BG
CRVS icon

BlackRock Group’s Corvus Pharmaceuticals CRVS Stock Holding History

BlackRock Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$72K Hold
5,062
– – ﹤0.01% 2877
2016
Q3 		$83K Hold
5,062
– – ﹤0.01% 2847
2016
Q2 		$72K Sell
5,062
-114,914
-96% -$1.55M ﹤0.01% 2854
2016
Q1 		$1.74M Buy
+119,976
New +$1.72M ﹤0.01% 1627

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock Group's CRVS Position: Q4 2016 in Review

BlackRock Group held its Corvus Pharmaceuticals (CRVS) position steady in Q4 2016 at 5,062 shares worth $72K. The position accounts for ﹤0.01% of the portfolio, ranked #2877.

BlackRock Group first reported a position in CRVS in Q1 2016 and has held it in 4 quarters since. The position peaked at $1.74M in Q1 2016. 53 funds tracked by Wall St. Rank hold CRVS as of Q4 2016.

  • BlackRock Group held 5,062 shares of Corvus Pharmaceuticals worth $72K as of Q4 2016.
  • BlackRock Group left its Corvus Pharmaceuticals share count unchanged in Q4 2016.
  • Corvus Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2877 holding.
  • BlackRock Group first reported a position in Corvus Pharmaceuticals in Q1 2016 and has held it in 4 quarters since.
  • BlackRock Group's Corvus Pharmaceuticals position peaked at $1.74M in Q1 2016.
  • 53 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.